# ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

> **NCT04829604** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ambrx, Inc.** · enrollment: 72 (actual)

## Conditions studied

- HER2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT04829604
- **Lead sponsor:** Ambrx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-26
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829604, "ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04829604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*